

Pursuant to the provisions of article 82 of the Spanish Securities Market Act (*Ley 24/1988, de 28 de julio, del Mercado de Valores*), Grifols, S.A. (“**Grifols**”) hereby notifies the National Securities Market Commission of the following

RELEVANT EVENT

On 9 January, 2014, New York time, Grifols has concluded the acquisition of a diagnostic business unit related to transfusion medicine and immunology of the Swiss company Novartis International AG (“**Novartis**”) for a total amount of US\$ 1,675 million (€ 1,240 million). The transaction, which was announced by means of a Relevant Event on November 11, 2013, has received all required legal and regulatory approvals.

The transaction has been structured through a newly created 100% Grifols-owned subsidiary, Grifols Chiron Diagnostics Corp.

This strategic operation will strengthen Grifols’ Diagnostic Division, particularly in the United States with a very strong and specialized commercial organization. It also diversifies Grifols’ business by promoting an activity area that complements the Bioscience Division (plasma proteins). Novartis’ diagnostic business, which focuses on guaranteeing the safety of blood donations for transfusion or to be used in the plasma fractionating industry, complements and extends Grifols’ existing product range. Grifols will become a vertically integrated company able to provide solutions for blood and plasma donor centers, with the most complete product portfolio in the immunohematology field: gel cards, multiscard and the new genotyping technology from Progenika.

Grifols estimates pro-forma total annual revenues to approach US\$1.0 billion (€740 million) for its Diagnostic Division after the closing of the transaction (including royalties).

As a result, the Diagnostic Division of Grifols will represent more than 20% of the group’s total income, compared to the current 4% and the company will accelerate its implementation of a new growth strategy based on promoting complementary activity areas. The transaction will increase Grifols’ workforce by approximately 550 employees as former Novartis employees are to be retained.

In Barcelona, 10 January 2014

Raimon Grifols Roura
Secretary to the Board of Directors